Vaxart Inc
Change company Symbol lookup
Select an option...
VXRT Vaxart Inc
CIHHF China Merchants Bank Co Ltd
BBY Best Buy Co Inc
BDGE Bridge Bancorp Inc
FFIC Flushing Financial Corp
TSC TriState Capital Holdings Inc
CSQPF Cervus Equipment Corp
IMXI International Money Express Inc
MDCO Medicines Co
TVETF Traverse Energy Ltd
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Closing Price
$2.11
Day's Change
0.03 (1.44%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.35
Day's Low
2.00
Volume
(Light)
Volume:
508,765

10-day average volume:
3,555,464
508,765

Activision Blizzard stock falls as 'Destiny' rights ceded to Bungie

4:28 pm ET January 10, 2019 (MarketWatch)
Print

Activision Blizzard Inc. (ATVI) shares fell in the extended session Thursday as the videogame publisher said it was ceding rights to the "Destiny" franchise to Bungie Inc. Activision shares dropped 6.7% after hours, following a 1% gain to close at $51.35 in the regular session. In a filing with the Securities and Exchange Commission, Activision said Bungie would assume "full publishing rights and responsibilities for the 'Destiny' franchise" and "will own and develop the franchise." Activision said it does not expect "material revenue, operating income or operating loss" from "Destiny" in 2019.

-Wallace Witkowski; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

January 10, 2019 16:28 ET (21:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.